Warren Buffett Adds To His Biotech Play

It’s no secret that Warren Buffett is a legendary investor. The decisions that he makes when trading on the stock market have been predominantly spot on for many years. That’s why investors pay attention to the moves that Berkshire Hathaway makes.

One recent move is that Berkshire Hathaway bought 217,597 shares of DaVita Inc. They paid a total of $109.76 per share. The total value of this purchase is $23.88 million. They made this trade last Friday, and it brought their total holding up to 10,483,112 shares of this company, and they are worth a total of $1.15 billion.

This isn’t the first time that Berkshire Hathaway increased their position in this company. As a matter of fact, they have been steadily adding to it over the last few months. Warren Buffett and company have actually added a total of 350,349 shares of DaVita between late September of this year, and early October. The price they paid for the shares were between $100.96 and $108.21 per share.

What does DaVita do? It’s actually the leading company in the United States for kidney care. They have clinics set up all over the country (even other parts of the world) and they help patients with chronic kidney failure. The patients go to the clinic if they can’t get the proper dialysis treatment when living with later stage renal disease. This company serves a total of 149,000 patients.

It’s no surprise that Warren Buffett and Berkshire Hathaway are making a long-term bet that the frequency of diabetes in the United States of America will increase.

Do you think it’s a good idea for Buffett to increase his bet in this company? Do you think it might be worth looking into for yourself? If you are a follower of Warren Buffett, then I highly recommend that you do so.

Leave a Reply

Your email address will not be published. Required fields are marked *